Episode Summary
In this episode of 340B Pulse, Muhammad Atif and Hassan speak with Kalvin Pugh, 340B Policy Director at CAN, a patient-centered policy institute focused on access, affordability, and advocacy across HIV, substance use, tuberculosis, and broader drug pricing issues. Kalvin brings a lived-experience lens to a program often debated in financial and legal terms. Diagnosed with HIV in 2016, he accessed medication through a state ADAP program largely funded by 340B rebates and now advocates before Congress and across the country for the program to operate as Congress intended.
The conversation centers on what it means to turn 340B savings into mission impact in today's environment. Kalvin anchors the discussion in statutory legislative intent: helping the safety net stretch scarce federal resources and reach more eligible patients with more comprehensive services. Mission impact, in practice, includes lower prices at the pharmacy counter, expanded access for uninsured and underinsured patients, and community investments such as FQHC dental vans. These are tangible outcomes that directly benefit patients rather than headlines disconnected from patient care.
Kalvin argues that gaps between savings and demonstrated impact are most visible where transparency is weakest, particularly among large health systems that face less reporting discipline than FQHCs and Ryan White AIDS Drug Assistance Programs. He distinguishes between entities that struggle to demonstrate impact and those that are unwilling to do so. He cites high-profile reports involving marketing expenditures, sports sponsorships, and misuse allegations as examples of why visibility and accountability matter just as much as the volume of savings generated.
Operational barriers receive equal attention. Contract pharmacy economics, particularly excessive fees charged to smaller mission-focused entities with limited negotiating leverage, are described as the largest current challenge reducing funds that should otherwise support patient care. Data visibility, HRSA audit readiness, and honest reporting are framed as prerequisites for demonstrating impact rather than optional compliance exercises.
The episode also covers the paused federal rebate-model pilot. Kalvin views a rebate approach as consistent with legislative intent and points to long-running state ADAP rebate models as evidence. The discussion explores the disconnect between policy hearings and patient-centered conversations, the growing alignment among patient advocacy groups, and what an ideal transparency framework could look like if modeled after FQHC and ADAP reporting standards. Kalvin closes with rapid-fire answers and practical advice: approach the program with the goal of expanding access for patients, because that is where durable program legitimacy begins.
Show Notes
- Defining "turning savings into mission impact" through full statutory legislative intent, not only stretch-resources language.
- Gaps between 340B savings generated and impact demonstrated, with transparency differences across entity types.
- Willingness versus ability to demonstrate patient and community outcomes.
- Patient-level signals of 340B working: pharmacy counter affordability, copay burden, and access expansion.
- Whether policy debate has overshadowed the patient access purpose of the program.
- Contract pharmacy fees, leverage asymmetry, and lawsuits by large hospital systems against chain pharmacies.
- Data limitations, reporting complexity, and HRSA audit readiness as visibility tools.
- Rebate-model pilot pause, state ADAP precedent, and expected legislative activity.
- Alignment between patient groups and policy goals versus disconnects with large-system transparency.
- Patient stories, community health outcomes, and standardized definitions of patient benefit.
- CAN's mission, history, and policy work across state and federal levels.
- Rapid-fire views on tracking savings, mission-impact definitions, and future policy emphasis.